A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

Summary

This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).

Timeline

Start

2024-06-13

Primary completion

2025-05-20

Completion

2026-04-21

Drugs

Indications